Mutation of four lysine residues in the p53 C-terminal domain inhibits MDM2-dependent ubiquitination of p53 and alters its subcellular distribution. This implies that modi®cation (such as acetylation and phosphorylation) of amino acid residues in p53 C-terminal domain, regulate the biological functions of p53. In this study, we demonstrated that p53 with lysine residues 372, 373, 381, and 382 mutated to alanine (the A4 mutant) retained the transactivation activity of wild-type p53, although the transactivation activity of p21 promoter by the A4 mutant was slightly reduced. The inducible expression of wild-type p53 and the A4 mutant in H1299 cells caused growth inhibition due to cell-cycle arrest. Consistent with previous studies, the expression of wild-type p53 elicited G 1 and G 2 arrests. However, the cells expressing the A4 mutant underwent G 1 arrest but not G 2 arrest. Cyclin B1-associated kinase activity was reduced in cells expressing wild-type p53 but not A4, when the cells underwent G 2 arrest. This suggests that modi®cation of the p53 C-terminal domain might inhibit p53-mediated G 2 arrest. In other words, p53 requires an intact C-terminus to induce G 2 arrest.
Introduction
p53 is a short-lived protein and it is often activated through posttranslational mechanisms following a variety of stress signals. DNA damage induces p53 posttranslational modi®cations, including phosphorylation (Shieh et al., 1997 (Shieh et al., , 1999 Oda et al., 2000; Unger et al., 1999; Chehab et al., 1999) and acetylation (Liu et al., 1999; Sakaguchi et al., 1998) . Phosphorylation of p53 Nterminus is thought to disrupt the interaction between p53 and its negative regulator, MDM2, and so reduce the transcriptional inhibition and degradation mediated by MDM2 (Shieh et al., 1997; Unger et al., 1999; Chehab et al., 1999) . In contrast, acetylation of sites within the Cterminus of p53 has been shown to stimulate DNA binding in vitro (Gu and Roeder, 1997) .
In response to genotoxic stress, mammalian cells activate cell-cycle checkpoints at the G 1 /S and G 2 /M transitions (Hartwell and Weinert, 1989) . The tumor suppressor protein p53 is an important regulator of these checkpoint functions (Cox and Lane, 1995; Gottlieb and Oren, 1996; Ko and Prives, 1996; Levine, 1997) p53 causes G 1 arrest in cells exposed to DNAdamaging agents by inducing p21
Waf1/Cip1 (p21), a protein that binds to and inactivates the cyclindependent kinases necessary for initiating DNA synthesis (Harper et al., 1993) , and when overexpressed in rat or human ®broblasts, p53 also inhibits the G 2 /M transition (Agarwal et al., 1995; Stewart et al., 1995) .
In this study, we found by cell cycle analysis that A4 mutant p53 was unable to elicit G2-M cell cycle block when transfected into p53 null H1299 cell line, suggesting the involvement of p53 C-terminus on G2-M check point function. The lysine residue at putative acetylation sites (372, 373, 381, 382) were altered to alanine residues (Figure 1 ). H1299 p53 de®cient cells were transiently transfected with either wild-type or mutant p53 cDNA and 24 h later, total protein was analysed by Western blot using p53 antibodies ( Figure  2 ). Although the A4 mutant was detected by PAb1801 which recognizes p53 amino acids 46 ± 55, the mutant was not detected by PAb421 which recognizes the p53 C-terminal domain. The level of A4 mutant protein was higher than that of wild-type p53, because A4 mutant is resistant to MDM2-mediated degradation (Shieh et al., 1997) . In addition, the A4 mutant obviously induced expression of endogenous p21 (Figure 2 ), suggesting that mutation of the four lysine residues in the C-terminal domain did not abolish the transactivation ability of p53.
To analyse the biological eect of such mutations in the C-terminal domain of p53, we established H1299 cell lines stably expressing either wild-type p53 or A4 mutant under the control of an ecdysone-inducible system. One of these lines, the pVg/RXR-transfectant R-11, served as a negative parental control cell line. Clones WT-18 and A4-38, which expressed inducible wild-type p53 and the A4 mutant, respectively, were selected and used for further studies. In both clones, the expression of p53 became detectable 4 ± 6 h after Oncogene (2002) 21, 2102 ± 2107 ã 2002 Nature Publishing Group All rights reserved 0950 ± 9232/02 $25.00 www.nature.com/onc incubation with 5 mM Ponesteron A (PA) and reached a maximum at 16 h (Figure 3 ). Endogenous p21 was detected 16 h after PA treatment (Figure 3) , indicating that the p53 proteins in both clones were able to act as transcriptional activators.
Next, the growth-inhibitory eect of p53 and A4 mutant was determined by using these inducible clones. PA treatment had only a marginal eect on R-11 cells (data not shown) but almost completely inhibited the growth of WT-18 and 4-38 cells (Figure 4a ). Because ectopic expression of wild-type p53 in H1299 cells has been shown to cause growth arrest or apoptosis (Chen et al., 1996; Haupt et al., 1996; Kagawa et al., 1997; Wang et al., 1998) , it seemed reasonable to assume that the growth-inhibitory eects on WT-18 and A4-38 clones are mediated by induction of wild-type p53 and the A4 mutant, respectively. Flow-cytometric analysis demonstrated that in both WT-18 and A4-38, the G 1 population increased and the S phase population decreased after PA treatment ( Figure 4b ). Interestingly, the WT-18 G 2 /M population was signi®cantly larger than the A4-38 one at 48 h (28.9 vs 11.9%, respectively).
In other words, more A4-38 cells than WT-18 cells accumulated in G 1 phase (85.0 vs 65.8%, respectively). PA treatment had virtually no eect on the cell cycle of R-11 cells. Consistent with previous study using the same system, these clones showed no evidence of apoptosis after PA treatment (Wang et al., 1998) . These ®ndings led us to compare further the ability of wildtype and A4 mutant protein in regulation of G2-M cell cycle checkpoints. Cells were synchronized by double thymidine block and PA was added to medium 6 h prior to release of cells from cell-cycle block at the G 1 /S boundary. Cell-cycle analysis of synchronized and PAtreated R-11 cells demonstrated successful blocking of the cell cycle at the G 1 /S boundary and release from it ( Figure 5a ). Before the release, the cells formed a single peak (G 1 /S). By 6 ± 8 h later, most cells reached G 2 /M, while a small portion stayed in G 1 . The cells in transition appeared to begin mitosis around 10 h after release and then progressed to the G 1 phase of the next cell cycle. In the absence of PA, R-11, WT-18 and A4-38, showed similar time courses of cell-cycle transition (data not shown). However, synchronized WT-18 cells treated with PA had a slower reduction in the G 2 /M in the population at 12 h so that about 30% of the cells remains in G 2 /M (Figure 5a,b) . In contrast, A4-38 cells treated with PA had a rapid reduction in the G 2 /M population, just as the parental R-11 cells did at 12 h, so that only 10 ± 15% of the cells stayed in G 2 /M. Thus, more cells were arrested somewhere between the G 2 and M phases after expression of wild-type p53 than after expression of the A4 mutant.
To analyse the kinetics of DNA synthesis after removal of thymidine, cells were incubated with BrdU for 2 h prior to harvest (Figure 5c ). The percentage of cells incorporating BrdU was comparable in all three clones at 6 h and decreased to similar extents up to 10 h. The percentage of BrdU-incorporating R-11 cells increased at 12 h, while that of WT-18 and A4-38 cells remained low. These results clearly indicate that the three clones had similar kinetics of DNA synthesis until they entered G 2 , and then WT-18 and A4-38 cells underwent cell-cycle arrest at G 1 and/or G 2 /M as a result of expression of p53.
The level of the cyclin B1-/CDC2 kinase complex, a known regulator of the G 2 /M transition, increases dramatically just before mitosis and drops to very low Figure 1 The functional domains of human p53 and the positions of mutations (highlighted) are displayed. As previously described, wild-type p53 cDNA was inserted into either pRc/CMV vector (Invitrogen) (WT/pRc) or ecdysone-inducible plasmid, pIND (Invitrogen). Point mutations in the C-terminal domain of wild-type p53 were introduced using an in vitro site-directed mutagenesis system (GeneEditor; Promega Corp.) according to the manufacturer's instructions Figure 2 Western blot analysis of wild-type p53 and the A4 mutant in transiently transfected p53-null H1299 cells. The cells were lyzed and the protein concentration of the extracts was measured using the bicinchoninic acid (BCA) protein assay kit (Pierce). Fifty micrograms of protein was separated by 10.0% SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to a nitrocellulose membrane (Hybond ECL; Amersham Pharmacia Biotech). p53 was detected using either p53 monoclonal antibody PAb1801 or PAb421 (Oncogene Research Products). p21/WAF1 was detected using the WAF1 monoclonal antibody EA10 (Oncogene Research Products). Finally, the proteins were detected using the ECL protocol (Amersham Pharmacia Biotech) levels in G 1 (Hunter and Pines, 1994) . Therefore, to determine eects of wild-type p53 and the A4 mutant protein on the G 2 /M transition, we measured cyclin B1-associated kinase activity. In the parental R-11 cells, the kinase activity was low up to 4 h after removal of the thymidine block and then increased until mitosis (12 h), after which there was a rapid reduction of activity (Figure 6a,b) . On the other hand, kinase activity was reduced in the cells expressing wildtype p53 between 6 and 10 h. The kinase activities of the three clones peaked at 10 h after removal of the thymidine block. However, at 10 h, A4-38 cells had kinase activity comparable to that of R-11 cells. We also examined the status of p53, p21, and cyclin B1 proteins in the synchronized cells using their monoclonal antibodies. The expression of wild-type p53 and the A4 mutant was successfully induced in WT-18 and A4-38 cells and coincided with p21 expression ( Figure  6c ). The total amounts of cyclin B1, CDC2 and phosphorylated CDC2 in the three clones were almost the same at 6 ± 10 h, when the cyclin B1-associated kinase activity was reduced in WT-18 cells ( Figure 6 ). These results suggested that the expression of wild-type p53 in WT-18 cells reduced the cyclin B1-associated kinase activity, resulting in G 2 arrest. In contrast, the induction of A4 mutant did not inhibit the cyclin B1-associated kinase activity without G 2 arrest. Both wildtype p53 and the A4 mutant induced endogenous p21 expression and caused G 1 arrest.
Consistent with previous studies, the expression of wild-type p53 caused G 1 and G 2 arrest in H1299 cell line. However, cells expressing the A4 mutant underwent G 1 arrest but not G 2 arrest, and cyclin B1-associated kinase activity was reduced in cells expressing wild-type p53, not in those expressing the A4 mutant. This suggests that modi®cation of the p53 Cterminal domain is perhaps involved in p53-mediated G 2 arrest function. In other words, p53 requires its Cterminus for prosecution of G 2 arrest.
The expression of wild-type p53 in the study reported here, just after the G 1 /S checkpoint and before the G 2 /M checkpoint, induced a G 2 arrest that was related to reduce cyclin B1-/CDC2 kinase activity. On the other hand, the expression of the A4 mutant caused neither G 2 arrest nor reduction in cyclin B1-/ CDC2 kinase activity. The reduction in the kinase activity was clearly detected in cells expressing wildtype p53 between 6 and 10 h after release from thymidine block. These results suggest that the mutations in the C-terminal domain of p53, impaired Figure 3 Inducible expression of wild-type p53 and the A4 mutant. Stable ecdysone-inducible cell lines (H1299 cells transfected with pVgRXR and pIND/p53 or pIND/A4) were grown in the presence or absence of the ecdysone analogue ponasterone A (PA) (Invitrogen) for dierent time intervals and at the indicated time points, the cells were harvested, and expression of p53 and the A4 mutant was analysed by Western blot analysis with anti-p53 antibody Pab1801. The induction of p21 was also analysed using WAF1 antibody (Oncogene Sciences) and blots were reprobed with actin antibody p53 C-terminus in G 2 arrest S Nakamura et al p53's ability to cause G 2 arrest. The transition from G 2 to M is regulated in part by the cyclin B1/CDC2 kinase complex (King et al., 1994) . The level of CDC2 is relatively high and remains constant through the cell cycle, whereas the level of cyclin B1 is strictly dependent on the phase of the cell-cycle and increases substantially during the G 2 /M transition. Recent studies have indicated several mechanisms by which p53 controls the G 2 checkpoint. In g-irradiated HCT116 human colorectal cancer cells, p53 inhibits G 2 /M progression at least in part, by inducing the expression of 14-3-3s protein (Hermeking et al., 1997) , which in turn enhances the nuclear export of CDC25 in response to DNA damage (Lopez-Girona et al., 1999) . The p53-regulated protein GADD45 reportedly plays a critical role in G 2 /M arrest induced by ultraviolet light or methyl methanesulfonate , through direct inactivation of cyclin B1-/ CDC2 kinase activity . In addition to the transactivation activity of p53, its transrepression activity also contributes to G 2 arrest. p53 has been demonstrated to downregulate the transcription of cyclin B1 and CDC2 (Innocente et al., 1999; Taylor et al., 1999; Yun et al., 1999) . Although the precise mechanism by which A4 mutant loses its ability to cause G2 delay is still unknown, the study reported here demonstrated that mutations in the C-terminal domain of p53 abolished p53's activity to cause G 2 arrest. It has been demonstrated that p53 interacts with coactivator p300/CBP and pCAF-1, and these proteins possess histone acetyl transferase activity (HAT). These interactions are critical for some of the p53 functions like stability of the protein (Ito et al., 2001) . Additionally, p53 has been shown to be a substrate for acetylation (Gu and Roeder, 1997) . Recent studies have demonstrated that some of these lysines are acetylated in vivo in response to DNAdamaging agents such as ionizing radiation and Oncogene p53 C-terminus in G 2 arrest S Nakamura et al ultraviolet light (Sakaguchi et al., 1998; Liu et al., 1999; Ito et al., 2001) , which activate cell-cycle checkpoints. The biological eect of acetylated p53 is not well de®ned. The ®rst study of acetylated p53 has shown that acetylated p53 enhanced DNA-binding activity in vitro (Gu and Roeder, 1997) . Moreover, a recent study suggested that acetylation increases stability of p53 protein under genotoxic stress (Ito et al., 2001) . This strongly suggests that cell-cycle arrest is accompanied by acetylation of p53 when cells expressing wild-type p53 undergo genotoxic stress. Substituting alanine for lysine would perhaps mimic the state of acetylation because A4 mutant have enhanced DNA binding activity and increased stability as a result of inhibition of MDM2-mediated ubiquitination . These data reported here demonstrated the p53 C-terminal domain regulated the biological functions of p53 protein and there is an existing possibility that acetylation of p53 may impair p53's ability to cause G2 arrest. The expression of p53 and p21. Synchronized and PA-treated R-11, WT-18, and A4-38 cells were lysed with SDS sample buer at the indicated time points. The protein lysates were analysed by Western blotting with anti-p53 antibody PAb1801, anti-p21 antibody EA10, anti-cyclin B1 antibody GNS1, anti-CDC2 antibody 17, and anti-phosphorylated (Tyr15) CDC2 antibody. P-CDC2, CDC2 phosphorylated at Tyr15 p53 C-terminus in G 2 arrest S Nakamura et al
